Butyric acid enhances in vivo expression of hTNF-α in transduced melanoma cell line

Adam Giermasz, Tomasz Grzela, Dominika Nowis, Marcin Makowski, Anna Czajka, Tomasz Stoklosa, Witold Lasek, Anna Dabrowska, Maciej Wiznerowicz, Andrzej Mackiewicz, Marek Jakóbisiak

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Butyric acid (NaBut) and its derivatives are well-known agents eliciting tumor cell differentiation and apoptosis. In experimental models, NaBut is also used to enhance the efficacy of viral vectors. With the use of B78 murine melanoma cells transduced with the retroviral vector containing human tumor necrosis factor a (hTNF-α) gene, we investigated the ability of NaBut to increase the cytokine expression. We observed an increase in hTNF-α expression in vitro after incubation with NaBut. We also describe that the NaBut pro-drug tributyrin is able to increase hTNF-α expression in transduced B78 cells in a tumor vaccination model in mice. This observation strongly suggests a novel potential role for NaBut and its derivatives in tumor therapy. It could be used not only as a therapeutic directly acting on tumor cells but, in parallel, as a genetic vaccine "enhancer".

Original languageEnglish (US)
Pages (from-to)4001-4004
Number of pages4
JournalAnticancer Research
Issue number6 A
StatePublished - 2001
Externally publishedYes


  • Cancer
  • Retroviral vector
  • Sodium butyrate
  • TNF-α
  • Tributyrin
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Butyric acid enhances in vivo expression of hTNF-α in transduced melanoma cell line'. Together they form a unique fingerprint.

Cite this